aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
aVenture is in Alpha: aVenture recently launched early public access to our research product. It's intended to illustrate capabilities and gather feedback from users. While in Alpha, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to temporarily present this information to showcase the product's potential, but you should not yet rely upon it for your investment decisions.
© aVenture Investment Company, 2025. All rights reserved.
44 Tehama St, San Francisco, CA 94105
Privacy Policy
aVenture Investment Company ("aVenture") is an independent venture capital research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals.
While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision.
aVenture does not offer investment advisory services and is not registered as an investment adviser. The data provided by aVenture does not constitute recommendations or advice, whether by methodology or a statement written by a staff member of aVenture.
Links to external websites do not imply endorsement or affiliation with aVenture. References or links to providers offering the ability to invest in a primary or secondary transaction in a company are for convenience purposes only. They are not solicitations or offers to buy or sell an investment. Remember that past performance does not guarantee future results, and venture capital and private assets should be a contributory part of a diversified portfolio.
Neuron23 Inc. is an early-stage biotechnology company dedicated to developing precision medicines for genetically defined neurological and immunological diseases. The company's mission is to create targeted therapies that address the underlying genetic causes of these conditions, aiming to improve patient outcomes and quality of life.
Neuron23 has made significant strides in the field of precision medicine, leveraging cutting-edge research and technology to identify and develop novel treatments. The company's efforts have garnered attention within the biotech community, positioning it as a promising player in the fight against complex diseases.
Operating Status
Active
Ownership Type(s)
Venture Capital, Private
Main Product(s)
Precision Medicines
Technology
Biotech
Tags
Healthtech
Model Types
Software
Customer Type(s)
Consumers
Geographic Exposure
Global
When was Neuron23 founded?
Neuron23 was founded in 2018.
Where is Neuron23's headquarters located?
Neuron23's headquarters is located in South San Francisco, CA, US.
When was Neuron23's last funding round?
Neuron23's most recent funding round was for $100M (USD) in March 2022.
How many employees does Neuron23 have?
Neuron23 has 61 employees as of Feb 4, 2024.
How much has Neuron23 raised to-date?
As of July 05, 2023, Neuron23 has raised a total of $213.5M (USD) since Mar 30, 2022.
Add Comparison
Total Raised to Date
$213.5M
USD
Last Update Mar 30, 2022
Last Deal Details
$100M
USD
Mar 30, 2022
Series C
Total Employees Over Time
61
As of Feb 2024
Neuron23 Address
681 Gateway Blvd
South San Francisco,
California
94080
United States
Source(s): This page includes data and analysis provided by the company, OpenAI, and our research analysts